heart failure
Conditions
Interventions
treatment group:colchicine
control group:standardized drug treatment
Sponsors
Nanjing Drum Tower Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with chronic heart failure(NYHA II-IV),ejection fraction =18,<80,admission because of acute decompensation of heart faiure or within 3 months of discharge: 1) Sign the written informed consent to participate in the trial. 2) Men or women aged 18 years or older and less than 80 years on the day of signing informed consent; 3) History of chronic heart failure (NYHA class II-IV), receiving standard drug therapy before heart failure decompensation; 4) Left ventricular ejection fraction < 40% measured by echocardiography within the first 12 months (the most recent measurement must be used to determine eligibility); 5) Meet one of the following criteria: A) Subject is male. B) The subject is not a woman of childbearing potential or C) the subject is a woman of childbearing potential but agrees to take contraceptive measures throughout the study.
Exclusion criteria
Exclusion criteria: 1) Cardiogenic shock; 2) Hemodynamic instability; 3) Patients with significant bleeding tendency or hematological diseases, or patients with bone marrow suppression; 4) bronchial asthma, severe obstructive pulmonary disease; 5) Patients with severe renal insufficiency (eGFR < 30ml/min/1.73 m2), or only one kidney or kidney transplant patients; 6) Patients with severe liver dysfunction (Child-Pugh class B or C); 7) Patients with severe gastrointestinal diseases, such as gastrointestinal malignancies, recurrent gastrointestinal ulcers, and severe elimination History of chemical tract bleeding, severe diarrhea in recent one month, etc.; 8) Patients with acute myocardial infarction in the past three months; 9) Patients with severe immune system diseases or gout, in the treatment of steroidal anti-inflammatory drugs, cytotoxic drugs or colchicine; 10) Taking strong CYP3A4 inhibitors (such as atazanavir, itraconazole, clarithromycin, thiazepam, etc.) or P-gp inhibitors (such as verapamil, erythromycin, cyclosporine, quinidine, propafenone, etc.); 11) Pregnant women, lactating or planning to become pregnant; 12) Acute or severe systemic infection; 13) Subjects are participating in clinical trials of other drugs or medical devices; 14) Any known drug or alcohol dependence, difficulty understanding the trial protocol, unable or follow up according to the trial protocol; 15) Patients who the investigators believe are not suitable for this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Activity to'lerance;ejection fraction;readmission rate;mortality; | — |
Countries
China
Contacts
Public ContactBiao XU
Nanjing Drum Tower Hospital
Outcome results
None listed